A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection
- Status
- COMPLETED
- Phase
- PHASE4
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
- Status
- COMPLETED
- Phase
- PHASE3
Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome
- Status
- COMPLETED
- Phase
- N/A
DPP4 Inhibition & Beta Cell Function
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
- Status
- UNKNOWN
- Phase
- PHASE1
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
- Status
- COMPLETED
- Phase
- PHASE2
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
- Status
- WITHDRAWN
- Phase
- PHASE2